Uniseed — Australia's National University Venture Fund
Australia
Australia's oldest university venture fund: since 2000, Uniseed has backed 74 start-ups across nine universities and CSIRO that raised A$1.64bn, …
Japan · Kyoto · See the Japan profile
Evidence: Descriptive / self-reported Top 54% 67/100 · Ask Evidence Copilot about this practice
Kyoto University's captive venture-capital arm has raised three funds worth over ¥54 billion since 2016 and built an 86-company deep-tech portfolio — deliberately funding the high-risk research-to-startup gap that Japan's cautious private VC market avoids.
Kyoto-iCAP is a wholly owned Kyoto University venture-capital subsidiary, certified under Japan's Industrial Competitiveness Enhancement Act, established in 2014 to fund and support deep-tech spin-outs from Kyoto University and other national universities.
It provides venture capital plus entrepreneur-in-residence and executive-coaching programmes to de-risk deep-tech startups before private investors get involved, drawing capital from limited partners including Bank of Kyoto, Astellas Pharma, Shimadzu and SMBC Trust.
Since 2016 it has raised three funds worth over ¥54 billion (Innovation Kyoto 2016: ¥16.001bn; Innovation Kyoto 2021: ¥18.14bn; Fund III: ~¥20bn) and built an 86-company portfolio spanning biotech (31), machinery/materials/energy (25), healthcare devices (16), IoT/AI (7) and food/agriculture (7); portfolio company Chordia Therapeutics listed on the Tokyo Stock Exchange in June 2024.
Own resources / municipal budget
Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.
Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.
Where this practice's information was retrieved from, and when.
Australia
Australia's oldest university venture fund: since 2000, Uniseed has backed 74 start-ups across nine universities and CSIRO that raised A$1.64bn, …
Australia
UniQuest, University of Queensland's tech-transfer firm since 1984, licensed the Gardasil HPV-vaccine IP and creates spin-outs. Audited UQ accounts confirm …
Belgium
Founded in 1972, KU Leuven's tech-transfer office LRD generated 3,142 industry collaboration agreements, 102 new patents and €152.6 million in …
South Africa
Since 2021, WHO and the Medicines Patent Pool have backed Afrigen Biologics in Cape Town to reverse-engineer and transfer mRNA …
Open full copilot Grounded in cited practices — always check the sources.